MCID: TNP001
MIFTS: 46

Tinea Pedis

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Tinea Pedis

MalaCards integrated aliases for Tinea Pedis:

Name: Tinea Pedis 12 43 15 17 71 32
Athlete's Foot 12 74 42 62
Dermatophytosis of Foot 12
Ringworm of Foot 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12403
ICD9CM 34 110.4
MeSH 43 D014008
SNOMED-CT 67 6020002
ICD10 32 B35.3
UMLS 71 C0040259

Summaries for Tinea Pedis

MedlinePlus : 42 Athlete's foot is a common infection caused by a fungus. It most often affects the space between the toes. Symptoms include itching, burning, and cracked, scaly skin between your toes. You can get athlete's foot from damp surfaces, such as showers, swimming pools, and locker room floors. To prevent it Keep your feet clean, dry, and cool Wear clean socks Don't walk barefoot in public areas Wear flip-flops in locker room showers Keep your toenails clean and clipped short Treatments include over-the-counter antifungal creams for most cases and prescription medicines for more serious infections. These usually clear up the infection, but it can come back. Centers for Disease Control and Prevention

MalaCards based summary : Tinea Pedis, also known as athlete's foot, is related to tinea manuum and erythrasma, and has symptoms including maceration, fissures and scaling. An important gene associated with Tinea Pedis is SQLE (Squalene Epoxidase), and among its related pathways/superpathways are NOD-like receptor signaling pathway and C-type lectin receptor signaling pathway. The drugs Naftifine and Luliconazole have been mentioned in the context of this disorder. Affiliated tissues include skin of foot, skin and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A dermatophytosis that results in fungal infection located in skin of foot, especially between the toes, has material basis in Trichophyton or has material basis in Epidermophyton and has symptom fissures, has symptom scaling, has symptom maceration, and eroded areas between the toes and on the plantar surface of the foot.

PubMed Health : 62 About athlete's foot: Many people will have athlete's foot at some time throughout their life. It is usually the gaps between the toes that are affected. Athlete's foot can normally be treated effectively with creams available from the pharmacy. To prevent athlete's foot from developing at all, it is important to keep your feet dry.

Wikipedia : 74 Athlete's foot, known medically as tinea pedis, is a common skin infection of the feet caused by fungus.... more...

Related Diseases for Tinea Pedis

Diseases related to Tinea Pedis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Related Disease Score Top Affiliating Genes
1 tinea manuum 33.2 CBSL B4GALNT2
2 erythrasma 31.3 HECTD4 DEFB4B
3 dermatomycosis 30.8 CYP51A1 CLEC7A CBSL B4GALNT2
4 candidiasis 30.6 DEFB4A CYP51A1 CLEC7A CARD9
5 tinea unguium 30.5 SQLE MSRA CBSL B4GALNT2
6 bursitis 30.4 PES1 HECTD4
7 tenosynovitis 30.2 PES1 HECTD4
8 nerve compression syndrome 30.1 PES1 HECTD4
9 cutaneous candidiasis 30.1 CLEC7A CLEC6A CARD9 B4GALNT2
10 tinea corporis 30.0 SQLE DEFB4A CLEC6A CBSL CARD9 B4GALNT2
11 nail disease 30.0 CLEC7A CLEC6A CARD9
12 tinea capitis 29.9 SQLE CLEC6A CBSL CARD9 B4GALNT2
13 dermatophytosis 29.8 TRIM4 SQLE HECTD4 DEFB4A CYP51A1 CLEC7A
14 tinea cruris 29.7 SQLE DEFB4A CYP51A1 CLEC6A CBSL CARD9
15 pityriasis versicolor 29.7 ZNF347 SQLE CLEC7A CLEC6A CBSL
16 superficial mycosis 29.6 ZNF347 CLEC7A CLEC6A CBSL B4GALNT2
17 oral candidiasis 29.6 DEFB4A CLEC7A CLEC6A CARD9
18 fungal infectious disease 29.6 CYP51A1 CLEC7A CLEC6A CBSL CARD9 B4GALNT2
19 dermatitis 10.7
20 skin disease 10.7
21 keratosis 10.6
22 dermatitis, atopic 10.5
23 candida glabrata 10.5
24 bacterial infectious disease 10.4
25 erysipelas 10.4
26 pustulosis of palm and sole 10.4
27 psoriasis 10.4
28 exanthem 10.4
29 cellulitis 10.4
30 overgrowth syndrome 10.4
31 esophageal candidiasis 10.3 CYP51A1 CARD9
32 ige responsiveness, atopic 10.3
33 kaposi sarcoma 10.3
34 mycosis fungoides 10.3
35 sarcoma 10.3
36 allergic hypersensitivity disease 10.3
37 vascular disease 10.3
38 contact dermatitis 10.3
39 spindle cell sarcoma 10.3
40 lichen planus 10.3
41 pompholyx 10.3
42 acute pericementitis 10.3 DEFB4B DEFB4A
43 penicilliosis 10.2 CLEC7A CARD9
44 achilles bursitis 10.2 PES1 HECTD4
45 otomycosis 10.2 CBSL B4GALNT2
46 heel spur 10.2 PES1 HECTD4
47 de quervain disease 10.2 PES1 HECTD4
48 tarsal tunnel syndrome 10.2 PES1 HECTD4
49 tibial neuropathy 10.2 PES1 HECTD4
50 osgood-schlatter's disease 10.2 PES1 HECTD4

Comorbidity relations with Tinea Pedis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Hypertension, Essential
Peripheral Vascular Disease Tinea Manuum
Venous Insufficiency

Graphical network of the top 20 diseases related to Tinea Pedis:



Diseases related to Tinea Pedis

Symptoms & Phenotypes for Tinea Pedis

Symptoms:

12
  • maceration
  • fissures
  • scaling

UMLS symptoms related to Tinea Pedis:


fever, pruritus, exanthema

GenomeRNAi Phenotypes related to Tinea Pedis according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.84 CYP51A1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.84 DEFB4A DEFB4B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-119 9.84 MSRA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.84 MSRA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.84 DEFB4A DEFB4B CYP51A1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-165 9.84 DEFB4A DEFB4B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-171 9.84 ZNF347
8 Increased shRNA abundance (Z-score > 2) GR00366-A-200 9.84 DEFB4A DEFB4B MSRA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.84 CYP51A1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.84 CYP51A1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.84 DEFB4A DEFB4B
12 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.84 CYP51A1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.84 CYP51A1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-71 9.84 CYP51A1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.84 ZNF347
16 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.84 MSRA

Drugs & Therapeutics for Tinea Pedis

PubMed Health treatment related to Tinea Pedis: 62

Athlete's foot can usually be treated effectively with creams, gels or sprays that are available from pharmacies without a prescription. These products contain an ingredient that stops the growth of the fungus or kills it. But the treatment does require some patience. Home remedies such as tea tree oil or foot baths containing herbal products are sometimes recommended. But there is no scientific that they are effective against athlete's foot. Tablets are also an option if athlete's foot cannot be successfully treated topically. But that is only rarely necessary and must be given careful consideration because the risk of side effects is higher.

Drugs for Tinea Pedis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naftifine Approved Phase 4 65472-88-0 47641 73342
2
Luliconazole Approved Phase 4 187164-19-8
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4 Antacids Phase 4
5 Anti-Ulcer Agents Phase 4
6 Gastrointestinal Agents Phase 4
7 Proton Pump Inhibitors Phase 4
8
Sertaconazole Approved, Investigational Phase 3 99592-32-2 65863
9
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
10
Econazole Approved Phase 3 27220-47-9 3198
11
Ciclopirox Approved, Investigational Phase 3 29342-05-0 2749
12 Pharmaceutical Solutions Phase 3
13
Nitric Oxide Approved Phase 2 10102-43-9 145068
14
Bifonazole Approved, Investigational Phase 2 60628-96-8 2378
15
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
16
Racepinephrine Approved Phase 2 329-65-7 838
17
Ethanol Approved Phase 2 64-17-5 702
18
Terbinafine Approved, Investigational, Vet_approved Phase 2 91161-71-6 5402 1549008
19
Polihexanide Approved, Investigational Phase 2 28757-47-3
20 Respiratory System Agents Phase 2
21 Antioxidants Phase 2
22 Endothelium-Dependent Relaxing Factors Phase 2
23 Anti-Asthmatic Agents Phase 2
24 Vasodilator Agents Phase 2
25 Bronchodilator Agents Phase 2
26 Neurotransmitter Agents Phase 2
27 Protective Agents Phase 2
28 Anti-Infective Agents, Local Phase 2
29 Anti-Inflammatory Agents Phase 2
30 Epinephryl borate Phase 2
31 Hypoglycemic Agents Phase 2
32 Disinfectants Phase 2
33 Biguanides Phase 2
34
Oxiconazole Approved Phase 1 64211-46-7, 64211-45-6 5361463
35
Glucosamine Approved, Investigational Phase 1 3416-24-8 439213
36
Butenafine Approved Phase 1 101828-21-1 2484
37
Cysteine Approved, Nutraceutical Phase 1 52-90-4 5862
38
Bradykinin Investigational Phase 1 58-82-2 439201
39 Kininogens Phase 1
40
protease inhibitors Phase 1
41 omega-N-Methylarginine Phase 1
42 HIV Protease Inhibitors Phase 1
43 Ginkgo Phase 1
44
Salicylic acid Approved, Investigational, Vet_approved 69-72-7 338
45
acetic acid Approved 64-19-7 176
46
Benzoic acid Approved, Investigational 65-85-0 243
47
carbamide peroxide Approved 124-43-6
48
Curcumin Approved, Experimental, Investigational 458-37-7 969516
49
Turmeric Approved, Experimental, Investigational
50
tannic acid Approved 1401-55-4

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
2 An Open-Label Study to Assess the Pharmacokinetics With Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
3 An Open-Label, Maximal Use Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Completed NCT02394340 Phase 4 Omeprazole 40 mg;Luliconazole Cream 1%
4 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
5 Efficacy Of Sertaconazole 2% (ERTACZO) in the Treatment of Interdigital Tinea Pedis With Once a Day Treatment for 4 Weeks Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
6 Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis Unknown status NCT03320486 Phase 3 Dapaconazole;Ketoconazole
7 Study Clinical, Multicenter, Phase III, to Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Like Tinea Foot, Tinea and Tinea Crural Body" Unknown status NCT01105013 Phase 3 Clotrimazole
8 A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis Completed NCT00750139 Phase 3 NAFT-500;Placebo 2-weeks;Naftin 1%;Placebo 4-weeks
9 A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Interdigital Tinea Pedis Completed NCT01353976 Phase 3 Econazole Nitrate Foam 1%
10 A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison of Econazole Nitrate Foam 1% vs Foam Vehicle and an Evaluator-Blinded Comparison of Econazole Nitrate Foam 1% and Econazole Nitrate Cream 1% in Subjects With Interdigital Tinea Pedis Completed NCT01358240 Phase 3 Econazole Nitrate Foam 1%;Vehicle Foam;Econazole Nitrate Cream 1%
11 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis Completed NCT01396811 Phase 3 33525;Placebo
12 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis Completed NCT01396785 Phase 3 33525;Placebo
13 Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Econazole Nitrate Cream, 1% (Renaissance Pharma, Inc.) to Econazole Nitrate Cream, 1% (Perrigo New York Inc.) in Tinea Pedis Completed NCT03129321 Phase 3 Econazole Nitrate Cream, 1%;Placebo
14 An Open-Label Study to Evaluate the Safety of Long-Term Administration of Product 33525 in Subjects With Tinea Pedis, Tinea Corporis, or Tinea Cruris Completed NCT01349998 Phase 3 Product 33525
15 A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis Completed NCT00802672 Phase 3 Ciclopirox Olamine Cream;Loprox Cream 0.77%;Placebo
16 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of Terbinafine Film Forming Solution, 1% (as Hydrochloride), in Patients With Tinea Pedis Completed NCT01433107 Phase 3 Terbinafine;Terbinafine Placebo
17 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01289015 Phase 3 NAFT-600 ( naftin 2 % gel );Placebo
18 A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints Completed NCT02633813 Phase 3 Naftifine hydrochloride 2%;Placebo;Naftin® 2% (Naftifine hydrochloride 2%)
19 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01290341 Phase 3 NAFT-600 (naftin 2 % gel);Placebo
20 A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd) to Ketoconazole Cream 2% (G&W Laboratories Inc.) in the Treatment of Tinea Pedis Completed NCT03824912 Phase 3 Ketoconazole Cream 2%;Ketoconazole Cream 2% (G&W Laboratories Inc.);Placebo
21 A Randomized,Double-blind,Vehicle-controlled, Parallel-design,Multiple-site Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) to Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc.) in the Treatment of Tinea Pedis. Recruiting NCT04203342 Phase 3 Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.);Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA);Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
22 A Double-Blind, Randomized, Parallel Group Comparison of Nizoral Cream (F012), Ketoconazole 2% Cream (F126) and Placebo (F000) in the Treatment of Interdigital Tinea Pedis Terminated NCT01110330 Phase 3 Placebo cream;Ketoconazole 2% cream (formulation F012) (Nizoral);Ketoconazole 2% cream (formulation F126)
23 Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis Withdrawn NCT02606383 Phase 3 Dapaconazole;Ketoconazole
24 A Blinded Placebo Controlled Clinical Trial To Evaluate Fungicidal Activity With The Topical Application Of Nitric Oxide Releasing Solution (Nors) In Subjects With Moderate To Severe Tinea Pedis (Athlete's Foot) Completed NCT02871011 Phase 2 Nitric Oxide;Water
25 A Blinded Placebo Controlled Single Cross-over Clinical Trial to Evaluate Fungicidal Activity With Topical Application of 1% Gaseous Nitric Oxide in Subjects With Moderate to Severe Tinea Pedis (Athlete's Foot) Completed NCT00771342 Phase 2 Nitric Oxide;Nitrogen
26 Phase 2 Study - A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Duration Finding Study Evaluating the Efficacy and Safety of Two Week and Four Week Once Daily Treatment of Luliconazole Cream 1% in Patients With Tinea Pedis Completed NCT00869336 Phase 2 Luliconazole Cream 1% - 2 wks;Placebo Comparator -2 wks;Luliconazole Cream 1% - 4 wks;Placebo Comparator - 4 wks
27 Three-Arm Trial of Novel Treatment for Tinea Pedis Completed NCT03135912 Phase 2 Experimental Drug SESC 01;Placebo;Terbinafine Hydrochloride
28 An Investigator-blind, Randomized, Multicenter, 5-arm, Placebo- and Active Controlled Parallel Group Pilot Trial to Explore the Efficacy and Tolerability of Topical Bifonazole Liquid Spray in Patients With Athlete's Foot. Completed NCT01013909 Phase 2 Bifonazole spray once daily;Bifonazole spray twice daily;Placebo;Placebo;Lamisil Once
29 A Multi-Center Randomized, Evaluator-Blinded, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1%, Econazole Nitrate 1% Cream, and Foam Vehicle in Subjects With Tinea Pedis Completed NCT00768599 Phase 2 Econazole Nitrate Cream 1%;Econazole Nitrate Foam 1%;Vehicle Foam
30 A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis Completed NCT00893880 Phase 2 1% gaseous Nitric Oxide blended in Oxygen
31 Phase IIa, Two-center, Randomized, Double Blind Study With Parallel Groups to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS 41003 Versus Corresponding Mono-substances in Patients With Inflammatory Tinea Pedis Completed NCT01096472 Phase 2 LAS41003;LAS189961;LAS189962
32 A Multi-Center, Randomized Comparative Study of the Pharmacokinetics of Econazole Nitrate 1% Foam and Econazole Nitrate 1% Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years Completed NCT01696799 Phase 2 Econazole Nitrate;placebo
33 A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis Completed NCT02842021 Phase 2 S2G6T-1;S2G6T-2;S2G6T-3;S2G6T-4
34 Clinical Study Protocol Number DBI-201. Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With Tinea Pedis Completed NCT04152226 Phase 2 J. Lividum
35 Non-inferiority Phase II Trial Comparing BL123 (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis Completed NCT02824926 Phase 2 Dapaconazole;Ketoconazole
36 A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Dose-Ranging Study Assessing Efficacy and Safety of SB208 and Vehicle Gel in Subjects With Interdigital Tinea Pedis Completed NCT02860052 Phase 2 SB208 2%;SB208 4%;SB208 16%;Vehicle Gel
37 Evaluation of Preclinical Toxicity of a Siddha Formulation Kandhaga Rasayanam ( KR ) and Its Therapeutic Efficacy in Padarthamarai ( Dermatophytoses ) by an Open Clinical Trial Completed NCT02238912 Phase 2 kandhaga rasayanam
38 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Moderate to Severe Interdigital Tinea Pedis Completed NCT01891305 Phase 2 VT-1161;placebo
39 Dose-Ranging Study of the Efficacy and Safety of Miconazole Oil Used for 7 or 14 Days Compared With Vehicle in the Treatment of Otomycosis Completed NCT03130738 Phase 2 7-Day Miconazole Oil (Miconazole 2%);14-Day Miconazole Oil (Miconazole 2%);14-Day Placebo - Oil Vehicle
40 EFFICACY AND SAFETY OF A SINGLE-APPLICATION TREATMENT USING TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION TREATMENT USING BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL Recruiting NCT03999437 Phase 2 TERBINAFINE HYDROCHLORIDE (1%);BUTENAFINE HYDROCHLORIDE (1%);Vehicle Control
41 Clinical Trial Protocol DBI-204 Double-Blind, Randomized, Placebo Controlled Trial of the Safety and Efficacy of DBI-001 Gel in Patients With Interdigital Tinea Pedis Recruiting NCT04315051 Phase 2 Cohort 1 J. Lividum
42 A Multicenter, Randomized, Double-Blinded, Parallel Group Comparison Study of the Safety and Efficacy of UHE-103 in Subjects With Moccasin-Type Tinea Pedis Active, not recruiting NCT03897257 Phase 2 UHE-103A1 cream;UHE-103A2 cream;UHE-103B cream;UHE-103A1B cream;UHE-103A2B cream
43 A Multi-Centre, International, Randomised, Vehicle Controlled, Parallel-Group, Double-Blinded Phase 2 Trial of BB2603 Topical Treatment in Subjects With Distal Subungual Onychomycosis (DSO) of the Toenail Not yet recruiting NCT04188574 Phase 2 BB2603-1;BB2603-3;BB2603-10;Vehicle
44 Phase III Study in Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis Completed NCT01524432 Phase 1 Anti-fungal agent (Clotrimazole) loaded microcapsules;Placebo
45 A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis Completed NCT00835510 Phase 1 Butenafine cream 1% manufactured by Taro;Lotrimin Ultra (butenafine) 1%;Butenafine Vehicle manufactured by Taro
46 A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site, Study Comparing Oxiconazole Nitrate Cream 1% (Taro Pharmaceuticals,Inc) to Oxistat® (Oxiconazole Nitrate Cream) Cream 1% (PharmaDerma) in the Treatment of Tinea Pedis Completed NCT01519752 Phase 1 Oxiconazole Nitrate Cream 1%;Oxiconazole Nitrate Cream 1% (Oxistat®);Placebo
47 A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Naftifine Hydrochloride Cream 2%and the Naftin® Cream 2% in Patients With Tinea Pedis Completed NCT02132260 Phase 1 Naftifine Hydrochloride Cream 2%;Naftin® (Naftifine Hydrochloride) Cream 2%;Placebo Topical Cream
48 Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Parallel Design Study to Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis. Completed NCT01580891 Phase 1 Naftifine HCl Cream 1%;Naftin® (Naftifine HCl) Cream 1%;Placebo topical cream
49 A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Butenafine Hydrochloride Cream, 1% and Reference Listed Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Interdigital Tinea Pedis. Completed NCT01580878 Phase 1 Butenafine Hydrochloride Cream, 1%;Lotrimin Ultra®;Butenafine Vehicle
50 A Phase Ib, Randomized, Double Blind, Placebo Controlled Study to Investigate the Pharmacokinetics, Safety and Efficacy of 3 Different Doses of W0027 and Placebo Capsules in Subjects With Clinically and Mycologically Proven MTTP Completed NCT00509275 Phase 1 W0027;Placebo

Search NIH Clinical Center for Tinea Pedis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


butenafine
Butenafine hydrochloride
ciclopirox
Ciclopirox olamine
Clioquinol
CLIOQUINOL PWDR
Econazole
Econazole Nitrate
Griseofulvin
Griseofulvin ultramicrosize
haloprogin
Ketoconazole
Miconazole
Miconazole Nitrate
MICONAZOLE NITRATE PWDR
naftifine
Naftifine hydrochloride
oxiconazole
Sodium Hypochlorite
sulconazole
Sulconazole nitrate
terbinafine
Terbinafine hydrochloride
Tolnaftate

Cochrane evidence based reviews: tinea pedis

Genetic Tests for Tinea Pedis

Anatomical Context for Tinea Pedis

The Foundational Model of Anatomy Ontology organs/tissues related to Tinea Pedis:

19
Skin Of Foot

MalaCards organs/tissues related to Tinea Pedis:

40
Skin, Testes, Thyroid, Myeloid, T Cells, Neutrophil

Publications for Tinea Pedis

Articles related to Tinea Pedis:

(show top 50) (show all 1304)
# Title Authors PMID Year
1
Skin Infections and Outpatient Burn Management: Fungal and Viral Skin Infections. 42 61
31995350 2020
2
A Case of Tinea Pedis in a Child Caused by Trichophyton interdigitale with Two Different Colony Phenotypes on Primary Culture. 42 61
31787732 2019
3
Editorial: From the athlete foot to the painful hip: applied anatomy and clinical relevance of anatomical specific features in lower limb pathologies. 42
31701160 2019
4
FT-IR investigation of Terbinafine interaction with stratum corneum constituents. 61
32376224 2020
5
Miracles of Herbal Phytomedicines in Treatment of Skin Disorders: Natural Healthcare Perspective. 61
32568024 2020
6
Epidemiological survey of 42 403 dermatophytosis cases examined at Nagasaki University Hospital from 1966 to 2015. 61
32293052 2020
7
Comparison of in vitro antifungal activity of novel triazoles with available antifungal agents against dermatophyte species caused tinea pedis. 61
32139093 2020
8
Erratum to "Comparison of in vitro antifungal activity of novel triazoles with old antifungal agents against dermatophyte species caused tinea pedis" [J. Mycol. Med. 30 (2020) 100935]. 61
32534827 2020
9
Species distribution of the main aetiologic agents causing skin dermatophytosis in Colombian patients: A 23-year experience at a Mycological Reference Center. 61
32163641 2020
10
A Phytochemical and Ethnopharmacological Recapitulation on Hamelia patens. 61
32227313 2020
11
Viability of pathogenic dermatophytes during a 4-week treatment with 1% topical luliconazole for tinea pedis. 61
31111903 2020
12
Use of MALDI-TOF MS for fungal species distribution of interdigital intertrigo in seafarers, Dakar, Senegal. 61
32417179 2020
13
Prevalence and risk factors of tinea pedis in Georgian Defense Forces. 61
32205330 2020
14
Anti-inflammatory effect of lanoconazole on 12-O-tetradecanoylphorbol-13-acetate- and 2,4,6-trinitrophenyl chloride-induced skin inflammation in mice. 61
31724251 2020
15
Whole-genome resequencing of Trichophyton rubrum provides insights into population differentiation and drug resistance. 61
31538279 2020
16
Analysis of cases managed by dermatological service in the Chinese peacekeeping level 1+ medical treatment facility in Lebanon, 2018-2019. 61
32111673 2020
17
Molecular identification of isolates of the Trichophyton mentagrophytes complex. 61
31929737 2020
18
Preparation, and Assessment of Antidermatophyte Activity of Miconazole-Urea Water-Soluble Film. 61
32308646 2020
19
Syphilis as Athlete's Foot: "The Great Imitator" Strikes Again. 61
31705478 2020
20
Consumer preferences of antifungal products for treatment and prevention of tinea pedis. 61
30661432 2019
21
Characterization of Skin Microbiome in Tinea Pedis. 61
31762504 2019
22
Trichophyton mentagrophytes and T interdigitale genotypes are associated with particular geographic areas and clinical manifestations. 61
31444823 2019
23
Characteristics, Associated Diseases, and Management of Gram-negative Toe-web Infection: A French Experience. 61
31502652 2019
24
Internal environment of footwear is a risk factor for tinea pedis. 61
31436337 2019
25
Superficial fungal infections. 61
31569324 2019
26
Epidemiology and dermatological comorbidity of seborrhoeic dermatitis: population-based study in 161 269 employees. 61
30802934 2019
27
[Influence of nutrition, common autoimmune diseases and smoking on the incidence of foot mycoses]. 61
31172201 2019
28
Fangchinoline, a Bisbenzylisoquinoline Alkaloid can Modulate Cytokine-Impelled Apoptosis via the Dual Regulation of NF-κB and AP-1 Pathways. 61
31466313 2019
29
Tinea manuum: A report of 18 cases observed in the metropolitan area of Milan and review of the literature. 61
30929271 2019
30
Structure-based design of δ-lactones for new antifungal drug development: susceptibility, mechanism of action, and toxicity. 61
30734157 2019
31
Epidemiology of dermatophytosis in northeastern Iran; A subtropical region. 61
31321333 2019
32
A Simple Interdigital Separator to Aid the Management of Tinea Pedis. 61
31149595 2019
33
Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient. 61
30768808 2019
34
Reference genes for accurate evaluation of expression levels in Trichophyton interdigitale grown under different carbon sources, pH levels and phosphate levels. 61
30944363 2019
35
The Inhibitory Effect of Essential Oils on Rhizopus stolonifer, Trichophyton mentagrophytes, and Microsporum gypseum. 61
30690523 2019
36
Multiple abscesses in the lower extremities caused by Trichophyton rubrum. 61
30894136 2019
37
Evaluation of drug susceptibility test for Efinaconazole compared with conventional antifungal agents. 61
30427072 2019
38
Differences Between Patient-Reported Versus Clinician-Observed Nonulcerative Signs and Symptoms of the Foot in Patients With Diabetes Mellitus. 61
30747799 2019
39
One Foot After Another-Fungal Foot Issues in Expedition Adventure Racing. 61
30718137 2019
40
A Practical Guide to Curing Onychomycosis: How to Maximize Cure at the Patient, Organism, Treatment, and Environmental Level. 61
30456537 2019
41
Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis. 61
31474693 2019
42
Detection of Trichophyton spp. from footwear of patients with tinea pedis. 61
31534072 2019
43
Estimated burden of serious human fungal diseases in Turkey. 61
30107069 2019
44
2016 Epidemiological Survey of Dermatomycoses in Japan. 61
31474694 2019
45
Development of a Footwear Sizing System in the National Football League. 61
30048212 2019
46
Influence of the cultivation medium and pH on the pigmentation of Trichophyton rubrum. 61
31504066 2019
47
Hyperhidrosis and its impact on those living with it. 61
30589248 2018
48
Epidemiological and clinical aspects of dermatophytoses in Eastern Slovakia: a retrospective three-year study. 61
30817878 2018
49
Epidemiological Survey of Human Dermatophytosis due to Zoophilic Species in Tehran, Iran. 61
30788309 2018
50
Exoproteome Analysis of Human Pathogenic Dermatophyte Species and Identification of Immunoreactive Proteins. 61
29952123 2018

Variations for Tinea Pedis

Expression for Tinea Pedis

Search GEO for disease gene expression data for Tinea Pedis.

Pathways for Tinea Pedis

Pathways related to Tinea Pedis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.39 DEFB4B DEFB4A CARD9
2
Show member pathways
11.04 CLEC7A CLEC6A CARD9

GO Terms for Tinea Pedis

Biological processes related to Tinea Pedis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cholesterol biosynthetic process GO:0045540 9.16 SQLE CYP51A1
2 sterol biosynthetic process GO:0016126 8.96 SQLE CYP51A1
3 defense response to Gram-positive bacterium GO:0050830 8.8 DEFB4B DEFB4A CARD9

Molecular functions related to Tinea Pedis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB4B DEFB4A

Sources for Tinea Pedis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....